Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 13/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632611 | 1.00 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL4562904 | 0.93 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL4402730 | 0.93 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL14029675 | 0.82 | PLK1 (0.38) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3567289 | 0.81 | PKM (0.39) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL3567288 | 0.81 | PKM (0.39) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL4354039 | 0.78 | AKR1C3 (0.41) | PLK1PLK3MAPTAKR1C3AKR1C2 | |
| SCHEMBL4354043 | 0.78 | AKR1C3 (0.41) | PLK1PLK3MAPTAKR1C3AKR1C2 | |
| SCHEMBL2983664 | 0.77 | AKR1C3 (0.43) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL2989966 | 0.77 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| EP-1924572-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SmithKline Beecham Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | PLK1 1718/4885PLK3 2097/4885CDK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.